• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

血清检测胸苷激酶1作为肺癌早期检测的一种手段。

Serum detection of thymidine kinase 1 as a means of early detection of lung cancer.

作者信息

Alegre Melissa M, Weyant Michael J, Bennett Daine T, Yu Jessica A, Ramsden Madison K, Elnaggar Atif, Robison Richard A, O'Neill Kim L

机构信息

Department of Microbiology and Molecular Biology, Brigham Young University, Provo, UT, 84602, U.S.A.

出版信息

Anticancer Res. 2014 May;34(5):2145-51.

PMID:24778016
Abstract

BACKGROUND

Thymidine kinase 1 (TK1) is a biomarker elevated in several malignancies, including lung cancer. Up-regulation of TK1 is an early event in carcinogenesis and therefore a target for early cancer detection. We have developed a novel Enzyme Linked Immunosorbent Assay (ELISA) to detect TK1 in serum.

MATERIALS AND METHODS

Forty patients with pulmonary nodules and 18 healthy individuals had their serum collected prior to surgery. All samples were analyzed using a radioassay and ELISA.

RESULTS

TK1 was significantly elevated in all lung cancer samples. Patients with stage I (n=16) and stage II (n=17) disease had significantly higher TK1 levels than controls. The area under the curve was 0.792, using 4.9 nM TK1 as cut-off, for early-stage lung cancer. The sensitivity and specificity were 75.0 and 83.3, respectively. TK1 concentration was a more sensitive and accurate indicator of lung cancer than TK1 activity.

CONCLUSION

TK1 is significantly elevated in serum from patients with stage I and stage II lung cancer as measured using the established ELISA. This novel TK1 ELISA is both sensitive and specific for the detection of early-stage and advanced lung cancer, and therefore may be an important tool in the management of this disease.

摘要

背景

胸苷激酶1(TK1)是一种在包括肺癌在内的多种恶性肿瘤中升高的生物标志物。TK1的上调是致癌过程中的早期事件,因此是早期癌症检测的靶点。我们开发了一种新型酶联免疫吸附测定法(ELISA)来检测血清中的TK1。

材料与方法

40例肺结节患者和18名健康个体在手术前采集血清。所有样本均采用放射免疫分析法和ELISA进行分析。

结果

所有肺癌样本中的TK1均显著升高。I期(n = 16)和II期(n = 17)疾病患者的TK1水平显著高于对照组。以4.9 nM TK1为临界值,早期肺癌的曲线下面积为0.792。敏感性和特异性分别为75.0和83.3。TK1浓度比TK1活性更敏感、准确地指示肺癌。

结论

使用已建立的ELISA法检测,I期和II期肺癌患者血清中的TK1显著升高。这种新型TK1 ELISA对早期和晚期肺癌的检测既敏感又特异,因此可能是该疾病管理中的重要工具。

相似文献

1
Serum detection of thymidine kinase 1 as a means of early detection of lung cancer.血清检测胸苷激酶1作为肺癌早期检测的一种手段。
Anticancer Res. 2014 May;34(5):2145-51.
2
Thymidine kinase 1 combined with CEA, CYFRA21-1 and NSE improved its diagnostic value for lung cancer.胸苷激酶1联合癌胚抗原、细胞角蛋白19片段和神经元特异性烯醇化酶可提高其对肺癌的诊断价值。
Life Sci. 2018 Feb 1;194:1-6. doi: 10.1016/j.lfs.2017.12.020. Epub 2017 Dec 14.
3
A New Sandwich ELISA for Quantification of Thymidine Kinase 1 Protein Levels in Sera from Dogs with Different Malignancies Can Aid in Disease Management.一种用于定量不同恶性肿瘤犬血清中胸苷激酶1蛋白水平的新型夹心酶联免疫吸附测定法有助于疾病管理。
PLoS One. 2015 Sep 14;10(9):e0137871. doi: 10.1371/journal.pone.0137871. eCollection 2015.
4
A clinical evaluation of the TK 210 ELISA in sera from breast cancer patients demonstrates high sensitivity and specificity in all stages of disease.对乳腺癌患者血清进行的TK 210酶联免疫吸附测定临床评估表明,该测定在疾病各阶段均具有高敏感性和特异性。
Tumour Biol. 2016 Sep;37(9):11937-11945. doi: 10.1007/s13277-016-5024-z. Epub 2016 Apr 14.
5
AroCell TK 210 ELISA for determination of TK1 protein: age-related reference ranges and comparison with other TK1 assays.AroCell TK 210 ELISA 用于测定 TK1 蛋白:与年龄相关的参考范围及与其他 TK1 检测方法的比较。
Biotechniques. 2020 Jun;68(6):334-341. doi: 10.2144/btn-2019-0148. Epub 2020 Apr 27.
6
Serum thymidine kinase 1 is a prognostic and monitoring factor in patients with non-small cell lung cancer.血清胸苷激酶1是非小细胞肺癌患者的一个预后和监测指标。
Oncol Rep. 2005 Jan;13(1):145-9.
7
Analytical and clinical characterization of an optimized dual monoclonal sandwich ELISA for the quantification of thymidine kinase 1 (TK1) protein in human blood samples.分析和临床特征优化双单克隆夹心 ELISA 法检测人血样本胸苷激酶 1 (TK1)蛋白。
PLoS One. 2022 Oct 6;17(10):e0275444. doi: 10.1371/journal.pone.0275444. eCollection 2022.
8
Serum thymidine kinase 1 activity as a pharmacodynamic marker of cyclin-dependent kinase 4/6 inhibition in patients with early-stage breast cancer receiving neoadjuvant palbociclib.血清胸苷激酶 1 活性作为接受新辅助帕博西尼治疗的早期乳腺癌患者细胞周期蛋白依赖性激酶 4/6 抑制的药效标志物。
Breast Cancer Res. 2017 Nov 21;19(1):123. doi: 10.1186/s13058-017-0913-7.
9
Thymidine kinase 1 as a tumor biomarker: technical advances offer new potential to an old biomarker.胸苷激酶 1 作为一种肿瘤标志物:技术进步为老标志物带来新的潜力。
Biomark Med. 2018 Sep;12(9):1035-1048. doi: 10.2217/bmm-2018-0157. Epub 2018 Jul 24.
10
Serum thymidine kinase 1 activity in the prognosis and monitoring of chemotherapy in lung cancer patients: a brief report.血清胸苷激酶 1 活性在肺癌患者化疗中的预后和监测作用:简要报告。
J Thorac Oncol. 2014 Oct;9(10):1568-72. doi: 10.1097/JTO.0000000000000276.

引用本文的文献

1
Increased levels of thymidine kinase 1 in malignant cell-derived extracellular vesicles.恶性细胞衍生的细胞外囊泡中胸苷激酶1水平升高。
Biochem Biophys Rep. 2024 Jun 21;39:101761. doi: 10.1016/j.bbrep.2024.101761. eCollection 2024 Sep.
2
A Novel Model Using Serum Thymidine Kinase 1 and Low-dose Computed Tomography Parameters to Predict Three-year Lung Cancer Risk in People with Pulmonary Nodules: A Retrospective Study.一种使用血清胸苷激酶1和低剂量计算机断层扫描参数预测肺结节患者三年肺癌风险的新模型:一项回顾性研究。
J Cancer. 2024 Jan 1;15(3):737-746. doi: 10.7150/jca.90428. eCollection 2024.
3
Bibliometric and visualized analysis of applying tumor markers in lung cancer diagnosis from 2000 to 2022.
2000年至2022年肿瘤标志物在肺癌诊断中应用的文献计量学与可视化分析
Cancer Innov. 2023 May 19;2(4):265-282. doi: 10.1002/cai2.74. eCollection 2023 Aug.
4
Development of a Novel Recombinant Full-Length IgY Monoclonal Antibody against Human Thymidine Kinase 1 for Automatic Chemiluminescence Analysis on a Sandwich Biotin-Streptavidin Platform for Early Tumour Discovery.开发一种新型重组全长 IgY 单克隆抗体,用于人胸苷激酶 1 的全自动化学发光分析,该抗体基于夹心生物素-链霉亲和素平台,用于早期肿瘤发现。
J Immunol Res. 2023 Mar 17;2023:7612566. doi: 10.1155/2023/7612566. eCollection 2023.
5
Analytical and clinical characterization of an optimized dual monoclonal sandwich ELISA for the quantification of thymidine kinase 1 (TK1) protein in human blood samples.分析和临床特征优化双单克隆夹心 ELISA 法检测人血样本胸苷激酶 1 (TK1)蛋白。
PLoS One. 2022 Oct 6;17(10):e0275444. doi: 10.1371/journal.pone.0275444. eCollection 2022.
6
Selection of human single domain antibodies (sdAb) against thymidine kinase 1 and their incorporation into sdAb-Fc antibody constructs for potential use in cancer therapy.针对胸苷激酶 1 的人源单域抗体 (sdAb) 的筛选及其纳入 sdAb-Fc 抗体构建体中,以潜在用于癌症治疗。
PLoS One. 2022 Mar 3;17(3):e0264822. doi: 10.1371/journal.pone.0264822. eCollection 2022.
7
Re-Discovery of Pyrimidine Salvage as Target in Cancer Therapy.嘧啶补救作为癌症治疗靶点的再发现。
Cells. 2022 Feb 20;11(4):739. doi: 10.3390/cells11040739.
8
Novel monoclonal antibodies against thymidine kinase 1 and their potential use for the immunotargeting of lung, breast and colon cancer cells.新型抗胸苷激酶1单克隆抗体及其在肺、乳腺和结肠癌细胞免疫靶向中的潜在应用。
Cancer Cell Int. 2020 Apr 16;20:127. doi: 10.1186/s12935-020-01198-8. eCollection 2020.
9
Relationship between thymidine kinase 1 before radiotherapy and prognosis in breast cancer patients with diabetes.放疗前胸苷激酶 1 与乳腺癌合并糖尿病患者预后的关系。
Biosci Rep. 2020 Apr 30;40(4). doi: 10.1042/BSR20192813.
10
Knockdown of Thymidine Kinase 1 Suppresses Cell Proliferation, Invasion, Migration, and Epithelial-Mesenchymal Transition in Thyroid Carcinoma Cells.抑制胸苷激酶1可抑制甲状腺癌细胞的增殖、侵袭、迁移及上皮-间质转化。
Front Oncol. 2020 Jan 29;9:1475. doi: 10.3389/fonc.2019.01475. eCollection 2019.